Archives 2026

Business Wire India

Kioxia Corporation, a world leader in memory solutions, today announced that it has begun shipping evaluation samples ⁽¹⁾ of embedded flash memory compatible with the next-generation UFS standard, UFS 5.0, which is currently being standardized by JEDEC. ⁽²⁾
UFS 5.0 is a new standard for embedded flash storage currently being developed by JEDEC to meet the performance requirements of next-generation mobile devices such as high-end smartphones equipped with on-device AI functions. It utilizes MIPI M-PHY version 6.0 for the physical layer and UniPro version 3.0 for the protocol. M-PHY version 6.0 introduces the new HS-GEAR6 mode, theoretically supporting an interface speed of up to 46.6 Gbps per lane; with 2 lanes, UFS 5.0 can achieve approximately 10.8 GB/s of effective read/write performance.

 

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260220218622/en/

 

 

 

The evaluation samples incorporate an in-house newly developed controller for UFS 5.0 and Kioxia’s 8th-generation BiCS FLASH™, and are available in capacities of 512 GB and 1 TB. The package has been newly designed with a small 7.5 x 13 mm size, contributing to board space efficiency and design flexibility.

 

The samples are provided to customers who are developing UFS 5.0-compatible host systems, enabling them to evaluate performance and conduct interoperability testing.

 

 

Kioxia will continue to introduce new flash memory technologies into its UFS products to meet the increasing demands for larger capacity and higher performance in the mobile market.

 

 

Notes:

 

 

1. These samples are intended for functional evaluation only. Specifications of the samples will differ from commercial products.
2. Shipments of 512 GB evaluation samples began on February 24, and shipments of 1 TB samples are scheduled to start from March onwards.

 

• In every mention of a Kioxia product: Product density is identified based on the density of memory chip(s) within the Product, not the amount of memory capacity available for data storage by the end user. Consumer-usable capacity will be less due to overhead data areas, formatting, bad blocks, and other constraints, and may also vary based on the host device and application. For details, please refer to applicable product specifications. The definition of 1 KB = 2^10 bytes = 1,024 bytes. The definition of 1 Gb = 2^30 bits = 1,073,741,824 bits. The definition of 1 GB = 2^30 bytes = 1,073,741,824 bytes. 1 Tb = 2^40 bits = 1,099,511,627,776 bits.

 

• 1 Gbps is calculated as 1,000,000,000 bits/s and 1 GB/s is calculated as 1,000,000,000 bytes/s.

 

 

• Company names, product names and service names may be trademarks of third-party companies.

 

 

About Kioxia

 

 

Kioxia is a world leader in memory solutions, dedicated to the development, production and sale of flash memory and solid-state drives (SSDs). In April 2017, its predecessor Toshiba Memory was spun off from Toshiba Corporation, the company that invented NAND flash memory in 1987. Kioxia is committed to uplifting the world with “memory” by offering products, services and systems that create choice for customers and memory-based value for society. Kioxia’s innovative 3D flash memory technology, BiCS FLASH™, is shaping the future of storage in high-density applications, including advanced smartphones, PCs, automotive systems, data centers and generative AI systems.

 

 

Information in this document, including product prices and specifications, content of services and contact information, is correct on the date of the announcement but is subject to change without prior notice.

 

 

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260220218622/en/

 

Business Wire India

 

Parents who have looked for the best birthday party idea for their children have had their wish fulfilled. Today, the Empire State Building (ESB) announced the debut of its first-ever ESB Birthday Party Package for kids at the international icon’s Observatory as part of year-long 95^th anniversary celebrations.

 

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260223161708/en/

 

 

 

“From Lego playtime to Percy Jackson readers, children love the Empire State Building and now parents can give an unmatched experience to their children and their friends,” said Anthony E. Malkin, chairman and CEO of Empire State Realty Trust. “This birthday party package tops them all with an escorted visit through our world-famous Observatory, a private party room with a Ghirardelli sundae chef, Empire State Building party favors, and so much more.”

 

The ESB Birthday Party Package includes a guided visit through the Observatory’s galleries and New York City’s best views on the 86^th Floor deck, a private party room with a Ghirardelli Chocolate & Ice Cream Shop sundae chef, artisanal snacks and drinks, professional face painting and balloon twisting, and ESB-themed evites and party favors. For the ultimate experience, celebrants can include a visit to the premium 102^nd Floor Observatory and can even add a visit from the Empire State Building’s beloved mascot, Emma Pire. The package includes a party for 12 children and three adults, which can be expanded to accommodate up to 25 guests. ESB Birthday Party Packages must be booked at least 28 days in advance at esbnyc.com and are available for celebrations on Saturdays and Sundays from 10 a.m. to 3 p.m.

 

 

The Empire State Building’s world-famous Observatory Experience recently underwent a $165 million upgrade that features an interactive museum with nine galleries, brand-new host uniforms, and a reimagined 102^nd Floor Observatory.

 

 

Hi-res imagery for the Empire State Building Observatory and its new Birthday Package can be downloaded here. More information about the Empire State Building and the ESB Birthday Party Package can be found online.

 

 

About the Empire State Building
The Empire State Building, the “World’s Most Famous Building,” owned by Empire State Realty Trust, Inc. (ESRT: NYSE), soars 1,454 feet above Midtown Manhattan from base to antenna. The $165 million reimagination of the Empire State Building Observatory Experience created an all-new experience with a dedicated guest entrance, an interactive museum with nine galleries, and a redesigned 102^nd Floor Observatory with floor-to-ceiling windows. The journey to the world-famous 86^th Floor Observatory, the only 360-degree, open-air observatory with views of New York and beyond, orients visitors for their entire New York City experience and covers everything from the building’s iconic history to its current place in pop culture. The Empire State Building Observatory Experience welcomes millions of visitors each year and is ranked the #1 Top Attraction in New York City for the fourth consecutive year in Tripadvisor’s 2025 Travelers’ Choice Awards: Best of the Best Things to Do, “America’s Favorite Building” by the American Institute of Architects, the world’s most popular travel destination by Uber, and the #1 New York City attraction in Lonely Planet’s Ultimate Travel List.

 

 

Since 2011, the building has been fully powered by renewable wind electricity, and its many floors house a diverse array of office tenants such as LinkedIn and Shutterstock, as well as retail options like STATE Grill and Bar, Tacombi, and Starbucks. For more information and Observatory Experience tickets visit esbnyc.com or follow the building’s Facebook, X (formerly Twitter), Instagram, Weibo, YouTube, or TikTok.

 

 

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260223161708/en/

 

Business Wire India

Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that it has entered into an agreement to exclusively license global rights to MIUDELLA, Sebela Pharmaceuticals’ hormone-free copper intrauterine device (IUD) contraceptive. The effectiveness of this transaction is subject to review under the Hart-Scott-Rodino Antitrust Improvements Act and to U.S. Food and Drug Administration (FDA) approval of MIUDELLA’s alternate supply chain entities and certain other conditions.

 

MIUDELLA, the first hormone-free copper IUD approved in the U.S. in the last 40 years, is complementary to Organon’s commercial capabilities and would further Organon’s commitment to building a portfolio of products that meet women’s diverse reproductive health needs. MIUDELLA was approved by the FDA on February 24, 2025, for the prevention of pregnancy in females of reproductive potential for up to three years and is not yet commercially available. MIUDELLA offers an additional option for women seeking long-acting, reversible, hormone-free contraception. MIUDELLA contains a unique flexible frame and a fully preloaded inserter with a small, tapered insertion tube diameter of 3.7mm.¹

 

Under the terms of the agreement, Organon will pay $27.5 million at closing, with potential sales-based milestone payments of up to $505 million, as well as tiered double-digit royalties based on net sales.

 

INDICATION FOR MIUDELLA®
MIUDELLA® is a copper-containing intrauterine system (IUS) indicated for prevention of pregnancy in females of reproductive potential for up to 3 years.

 

IMPORTANT SAFETY INFORMATION

 

• WARNING: Improper insertion of intrauterine systems, including MIUDELLA^®, increases the risk of complications.
• Proper training prior to first use of MIUDELLA^® can minimize the risk of improper insertion.
• MIUDELLA^® is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the MIUDELLA^® REMS program to ensure healthcare providers are trained on the proper insertion of MIUDELLA^® prior to first use. Further information is available at miudellarems.com and 1-855-337-0772.

 

CONTRAINDICATIONS:

• Use is contraindicated when one or more of the following conditions exist:
  • Pregnancy or suspicion of pregnancy, congenital or acquired abnormalities of the uterus, including leiomyomas, resulting in distortion of the uterine cavity, acute pelvic inflammatory disease (PID), postpartum endometritis or postabortal endometritis in the past 3 months, known or suspected uterine or cervical malignancy, for use as post-coital contraception (emergency contraception), uterine bleeding of unknown etiology, untreated acute cervicitis or vaginitis or other lower genital tract infection, conditions associated with increased susceptibility to pelvic infections, Wilson’s disease, a previously placed IUS that has not been removed, hypersensitivity to any component of MIUDELLA®, including polypropylene, copper, nitinol, an alloy of nickel and titanium, or any trace elements present in the copper components of MIUDELLA®. Persons with allergic reactions to these components may suffer an allergic reaction to this intrauterine system. Prior to placement, patients should be counseled on the materials contained in the IUS, as well as potential for allergy/hypersensitivity to these materials.

 

WARNINGS AND PRECAUTIONS:

• Risk of Complications Due to Improper Insertion: Improper insertion of intrauterine systems, including MIUDELLA®, increases the risk of perforation, infection, undiagnosed abnormal bleeding, pregnancy loss (if pregnancy occurs with MIUDELLA® in situ), and expulsion. Proper training prior to first use can minimize the risk of improper insertion. MIUDELLA® is available only through a restricted program under a REMS.
• MIUDELLA® REMS: MIUDELLA® is only available through a restricted program under a REMS called MIUDELLA® REMS Program to ensure all healthcare providers are trained prior to first use. Notable requirements include the following:
  • Healthcare providers must be certified with the program by enrolling and completing training on the proper insertion of MIUDELLA® prior to first use.
  • Pharmacies and healthcare settings that dispense MIUDELLA® must be certified by enrolling in the REMS and must only dispense MIUDELLA® to certified healthcare providers.
  • Further information is available at miudellarems.com and 1-855-337-0772.
• Ectopic Pregnancy: Promptly evaluate females who become pregnant for ectopic pregnancy while using MIUDELLA®.
• Intrauterine Pregnancy: Increased risk of spontaneous abortion, septic abortion, premature delivery, sepsis, septic shock, and death if pregnancy occurs. Remove MIUDELLA® if pregnancy occurs with MIUDELLA® in place and the thread ends are visible or can be retrieved from the cervical canal.
• Sepsis: Group A streptococcal infection has been reported following insertion of other IUSs; strict aseptic technique is essential during insertion.
• Pelvic Infection: Promptly evaluate patients with complaints of fever or lower abdominal pain after insertion of MIUDELLA®. Remove MIUDELLA® in cases of recurrent pelvic inflammatory disease or endometritis, or if an acute pelvic infection is severe or does not respond to treatment.
• Perforation: May reduce contraceptive effectiveness and require surgery. Risk is increased if inserted in postpartum and lactating females and may be increased if inserted in females with fixed, retroverted uteri or noninvoluted uteri. If perforation is suspected or occurs during placement, MIUDELLA® should be removed.
• Expulsion: Partial or complete expulsion may occur. Remove a partially expelled MIUDELLA®.
• Wilson’s Disease: MIUDELLA® may exacerbate Wilson’s disease, a rare genetic disease affecting copper excretion; therefore, the use of MIUDELLA® is contraindicated in females with Wilson’s disease.
• Bleeding Pattern Alterations: Menstrual bleeding may be altered and result in heavier and longer bleeding with spotting.
• MRI Safety Information: Patients using MIUDELLA® can be safely scanned with MRI only under certain conditions.
• Medical Diathermy: Medical equipment that contains high levels of Radiofrequency (RF) energy such as diathermy may cause health effects (by heating tissue) in females with a metal-containing IUS including MIUDELLA®. Avoid using high medical RF transmitter devices in females with MIUDELLA®.

 

ADVERSE REACTIONS: Most common adverse reactions (≥5%) are: heavy menstrual bleeding, dysmenorrhea, intermenstrual bleeding, pelvic discomfort, procedural pain, pelvic pain, post procedural hemorrhage, dyspareunia.

MIUDELLA® does not protect against human immunodeficiency virus (HIV) or other sexually transmitted infections (STIs).

 

Before prescribing MIUDELLA®, please read the full Prescribing Information, including Boxed Warning.

 

About Organon
Organon (NYSE: OGN) is a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. With a portfolio of over 70 products across Women’s Health and General Medicines, which includes biosimilars, Organon focuses on addressing health needs that uniquely, disproportionately or differently affect women, while expanding access to essential treatments in over 140 markets.

 

Headquartered in Jersey City, New Jersey, Organon is committed to advancing access, affordability, and innovation in healthcare. Learn more at www.organon.com and follow us on LinkedIn, Instagram, X, YouTube, TikTok and Facebook.

 

Cautionary Note Regarding Forward-Looking Statements
Except for historical information, this press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, but not limited to, statements about the potential benefits of Organon’s exclusive license of global rights to MIUDELLA^®. Forward-looking statements may be identified by words such as “will,” “potential,” “future,” “can,” “may,” “would,” or words of similar meaning. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate, or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include, but are not limited to, any review under the Hart-Scott-Rodino Antitrust Improvements Act, failure to secure FDA approval of MIUDELLA’s supply chain or otherwise satisfy the conditions of the transaction; weakening of economic conditions that could adversely affect the level of demand for MIUDELLA^®; pricing pressures globally, including rules and practices of managed care groups, judicial decisions and governmental laws and regulations related to or affecting Medicare, Medicaid and healthcare reform, pharmaceutical pricing and reimbursement, access to the company’s products, international reference pricing, including most-favored-nation drug pricing, and other pricing related initiatives and policy efforts; the impact of tariffs and other trade restrictions or domestic sourcing requirements; expanded brand and class competition in the markets in which the company operates; the failure of any supplier to provide substances, materials, or services as agreed, or otherwise meet their obligations to the company; the increased cost of supply, manufacturing, packaging, and operations; difficulties developing and sustaining relationships with commercial counterparties, including Sebela Pharmaceuticals; the impact of higher selling and promotional costs; efficacy, safety or other quality concerns with respect to the company’s marketed products, whether or not scientifically justified, leading to product recalls, withdrawals, labeling changes or declining sales; future actions of third parties, including significant changes in customer relationships or changes in the behavior and spending patterns of purchasers of healthcare products and services, including delaying medical procedures, rationing prescription medications, reducing the frequency of physician visits and forgoing healthcare insurance coverage; the failure by the company or its third party collaborators and/or their suppliers to fulfill their or their regulatory or quality obligations; and volatility of commodity prices, fuel, and shipping rates that impact the costs and/or ability to supply the company’s products. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s filings with the SEC, including the company’s most recent Annual Report on Form 10-K and subsequent SEC filings (including amendments thereto), available at the SEC’s Internet site (www.sec.gov). References and links to websites have been provided for convenience, and the information contained on any such website is not a part of, or incorporated by reference into, this press release. Organon is not responsible for the contents of third-party websites.

 

__________________________________

1 Creinin MD, Gawron LM, Roe AH, et al.; Copper 175mm2 IUD Phase 3 Clinical Investigator Group. Three-year efficacy, safety, and tolerability outcomes from a phase 3 study of a low-dose copper intrauterine device. Contraception. 2024 Nov 22:110771. doi: 10.1016/j.contraception.2024.110771.

 

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260223700923/en/

 

Business Wire India

 

• Angelini Pharma secures exclusive global license rights to future identified drug targets
• Quiver receives undisclosed advance payment and is eligible for future milestone-dependent payments and royalties
• Collaboration further expands Angelini Pharma’s focus on brain health, building on its deep therapeutic expertise and drug development experience

 

Angelini Pharma, part of the privately owned Angelini Industries, and Quiver Bioscience (“Quiver”), a discovery technology and therapeutics company advancing programs for the treatment of central nervous system (CNS) disorders, announced today that they have entered into a collaboration and licensing agreement to advance novel therapeutics for genetic epilepsies. The collaboration brings together Quiver’s unique drug discovery capabilities, data assets, and AI models with Angelini Pharma’s established expertise in brain health and epilepsy drug development.

 

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260223465174/en/

 

 

Under the terms of the multi-year agreement, Quiver will receive an undisclosed advance payment and support for defined research activities along with additional licensing fees granting Angelini Pharma exclusive access to collaboration-generated data during the research term. Quiver is also eligible to receive additional milestones payments of up to $120 million and additional royalties upon Angelini’s election of drug targets identified through the collaboration.

 

 

“The prospects of our collaboration with Quiver Bioscience are very promising,” said Rafal Kaminski, MD, PhD, Chief Scientific Officer at Angelini Pharma.” The aim is to generate novel scientific insights on a scale and richness that has been unprecedented in this area of research. By applying cutting-edge technologies and advanced data analytics approaches, including AI, this partnership will generate a unique data set to inform the development of novel therapies in the future.”

 

 

In its latest collaboration, Angelini Pharma will leverage Quiver’s technology platform to break new grounds in deeper understanding a broad set of Developmental and Epileptic Encephalopathies (DEEs). DEEs are a group of rare diseases affecting children worldwide, causing a spectrum of neurodevelopmental symptoms and severe treatment-resistant seizures linked to genetic mutations. They are often caused by gene mutations, but functional and molecular consequences of such mutations are not well understood in most cases. Despite introduction of recently approved treatments for some DEEs, there is still a pressing unmet need for more effective therapies. Quiver Bioscience’s advanced platform uses human neuronal models coupled with single-cell transcriptomic resolution, optical electrophysiology, and AI to accelerate the discovery of precision therapies for these complex conditions. The ultimate goal of the partnership is to discover and develop differentiated therapeutics that can address multiple DEEs.

 

 

“We’re excited to embark on this collaboration with the excellent team at Angelini Pharma,” said Graham T. Dempsey, PhD, Co-founder and Chief Executive Officer at Quiver Bioscience. “Together we are pursuing a novel approach uniquely enabled by Quiver’s technology platform. By leveraging altered electrophysiology in response to genetic perturbations as the core neuronal classifier and integrating paired multi-modal data, we aim to link functional phenotypes with the underlying molecular drivers. We look forward to translating this science into new medicines for a disease area in urgent need of innovation.”

 

 

“This new partnership is another step forward to advance our strategic priorities, strengthen our global presence and potentially expand our pipeline of innovative medicines and promising candidates”, said Sergio Marullo di Condojanni, Chief Executive Officer at Angelini Pharma. “It follows a number of strategic acquisitions and collaboration agreements that we have entered over the course of the past two years and will further boost our leadership and portfolio in brain health”.

 

 

Destum Partners acted as transaction advisor to Quiver Bioscience.

 

 

About Quiver Bioscience

 

 

Quiver Bioscience is a technology-driven biotechnology company focused on accelerating discovery of empirically grounded, AI-driven therapeutics that deliver transformative value to patients with neurological disease. Quiver has built the first-of-its kind perturbation atlas of neuronal behavior using its proprietary Genomic Positioning System (GPS) platform, enabling precise target identification, functional validation, and safety assessment. Their empirical-in-a-loop approach integrates scalable human neuronal models, advanced single-cell optical electrophysiology and multi-omics techniques, with machine learning and surrogate models, to identify novel therapeutic targets and optimal candidate molecules. For information, including scientific publications describing the application of Quiver’s GPS platform to drug discovery, visit www.quiverbioscience.com.

 

 

About Angelini Pharma

 

 

Angelini Pharma is an international pharmaceutical company, part of the privately owned multi-business Angelini Industries. The Company researches, develops and commercializes health solutions with a focus on the areas of Brain Health, including Mental Health and Epilepsy, and Consumer Health. Founded in Italy at the beginning of the 20th century, Angelini Pharma operates directly in 20 countries, employing more than 3,000 people. Its products are marketed in over 70 countries through strategic alliances with leading international pharmaceutical groups. More information: https://www.angelinipharma.com.

 

 

About Angelini Industries

 

 

Angelini Industries is a multinational industrial group founded in Ancona in 1919 by Francesco Angelini. Today, Angelini Industries represents a solid and diversified industrial reality that employs approximately 5,800 employees and operates in 21 countries around the world with revenues of over 2 billion euros, generated in the health, industrial technology, and consumer goods sectors. A targeted investment strategy for growth; constant commitment to research and development; deep knowledge of markets and business sectors, make Angelini Industries one of the Italian companies of excellence in the sectors in which it operates. To learn more visit https://www.angeliniindustries.com.

 

 

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260223465174/en/

 

Business Wire India

• Global commercial leader with 21 systems sold to 13 customers to date – including 4 out of the top 10 supercomputing centres globally.
• Industrial leader with 15 systems delivered (largest number publicly disclosed by selected quantum companies¹), 30+ computers built, own chip factory and quantum data centre.
• The transaction values IQM at a pre-money equity valuation of approximately USD 1.8 billion and makes IQM the first European quantum company to go public.
• With the close of this transaction, IQM’s cash position expected to exceed USD 450 million.²
• Significant business momentum, with at least USD 35 million³ 2025 revenue (unaudited) and over USD 100 million bookings / visibility as of year-end 2025.
• Strong commercial integrations with high-performance computing and enterprise platforms across the quantum/AI value chain such as NVIDIA, Hewlett Packard Enterprise, AWS, Toyo Corporation and Bechtle AG.
• Technical successes, achieving greater than 99.9% fidelity for single-qubit and two-qubit gates and readouts in their processors, and on track to deliver broad commercialization with the release of its next generation system, Halocene.

 

IQM Finland Oy, a global leader in full-stack superconducting quantum computers (“IQM”, “IQM Quantum Computers” or the “Company”), and Real Asset Acquisition Corp. (Nasdaq: RAAQ), a special purpose acquisition company (“RAAQ”), today announced they have entered into a definitive business combination agreement, which will result in IQM becoming a public company and listing American Depositary Shares on one of the two leading U.S. stock exchanges. The transaction provides funding with the aim to accelerate IQM’s technology and commercial development towards fault-tolerance quantum computing, further advancing its position as a leading provider of quantum computers.

 

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260223639678/en/

 

 

 

Headquartered in Finland, IQM is also considering a dual listing that would see the trading of IQM’s ordinary shares on the Helsinki stock exchange, which would be expected to take place following the completion of this transaction.

 

IQM is a quantum computing company that builds full stack, open-architecture systems that can be deployed on-premise or accessed via the cloud. IQM operates a vertically integrated business model, boasting a unique combination of proprietary infrastructure from their own chip design tool and software developer platform, to a quantum chip fab, assembly line and data centre, allowing the company to accelerate its innovation cycles, deliver best-in-class quantum computing to its customers and enabling the quantum ecosystem to grow.

 

 

Transaction Highlights:

 

 

Following completion of the transaction, IQM’s cash on its balance sheet is expected to be in excess of USD 450 million cash at closing⁴ (including IQM’s existing cash), providing runway for continued broad commercial advantage:

 

 

• Approximately USD 175 million of cash held in RAAQ’s trust account (based on the current amount in the trust account and assuming no redemptions);
• Approximately USD 134 million in proceeds from a PIPE financing at USD 10.00 per share from leading new and existing and institutional investors, to close concurrently with the business combination, subject to the satisfaction of certain customary closing conditions;
• Expected USD 24 million in proceeds from the cash exercise of outstanding IQM warrants prior to the closing;
• Existing cash on IQM’s balance sheet of USD 172 million (unaudited as of year-end 2025); and
• The transaction values IQM at a pre-money equity valuation of approximately USD 1.8 billion.

 

 

Jan Goetz, Co-Founder and Chief Executive Officer, IQM,said: “We built IQM from the beginning for one purpose — to put working quantum computers in the hands of the people who will use them to solve real problems. Not someday. Now. Quantum computing is a science project no more. It is an industry where customers own, operate, and build on advanced quantum computers. That’s what IQM makes possible.”

 

Peter Ort, Chief Executive Officer and Co-Chairman, Real Asset Acquisition Corp, said: “IQM has built and delivered more on-premises quantum systems than any other competitor⁵ — to some of the most demanding research institutions on earth. This transaction will accelerate the growth of a company that has already earned its position in the field, with real customers, running real quantum systems, today.”

 

 

Sierk Poetting, Chairman of IQM’s Board of Directors, said: “Going public is not a change of direction but is rather an acceleration. The board stands fully behind IQM’s mission and goals to make quantum infrastructure as foundational and accessible as classical computing.”

 

 

The existing IQM shareholders will not sell any shares or receive any cash consideration as part of the transaction and all material IQM shareholders have committed to a customary lock-up agreement at close of this transaction.

 

 

The board of directors of both IQM and RAAQ have each unanimously approved the proposed business combination. The closing of the proposed business combination is subject to, among other things, the approval by shareholders of RAAQ and IQM of the business combination agreement and the satisfaction of other customary closing conditions.

 

 

Additional information about the proposed business combination, including a copy of the business combination agreement, will be provided in a Current Report on Form 8-K to be filed by RAAQ with the Securities and Exchange Commission (the “SEC”).

 

 

The securities being sold in the PIPE financing have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or applicable state securities laws and accordingly may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws.

 

 

This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

 

 

Conference Call Information

 

 

Management of IQM and RAAQ will host an investor conference call to discuss the proposed transaction and review an investor presentation, with exact details to be updated and confirmed with a follow-up announcement. Interested investors will be able to access a recording of the conference call by visiting https://meetiqm.com/investors/. A transcript of the call will also be filed by RAAQ with the SEC.

 

 

Advisors

 

 

J.P. Morgan SE is serving as financial advisor and capital market advisor to IQM. J.P. Morgan Securities LLC and TD Cowen are serving as PIPE placement agents to IQM. Rothschild & Co. is serving as financial advisor and capital markets advisor to IQM’s and its Board of Directors. TD Cowen is serving as financial advisor and capital markets advisor to RAAQ. Cohen & Company Capital Markets is serving as a capital markets advisor to RAAQ. Cooley LLP and Borenius Attorneys Ltd are serving as legal advisors to IQM, and Perkins Coie LLP, Krogerus Attorneys Ltd and Conyers Dill & Pearman LLP are serving as legal advisors to RAAQ. DLA Piper LLP (US) is serving as legal advisor to J.P. Morgan Securities LLC and TD Cowen. The Blueshirt Group is serving as investor relations advisor to IQM.

 

 

About IQM Quantum Computers

 

 

IQM Finland Oy (“IQM”, “IQM Quantum Computers”, “Company”) is a global leader in superconducting quantum computers. IQM provides both on-premises full-stack quantum computers and a cloud platform to access its systems. IQM customers include leading high-performance computing centres, research laboratories, universities, and enterprises that require full access to quantum hardware and software. IQM has over 300 employees, with headquarters in Finland and a global presence including France, Germany, Italy, Japan, Poland, Saudi Arabia, Spain, Singapore, South Korea, Taiwan, UK and the United States.

 

 

About Real Asset Acquisition Corp.

 

 

Based in Princeton, NJ, Real Asset Acquisition Corp. is a Nasdaq-listed (Nasdaq: RAAQ) special purpose acquisition company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The RAAQ team includes seasoned quantum computing experts with deep technical and industry experience.

 

 

¹ Represent publicly announced on-premises deliveries from each of IBM, D-Wave, Pasqal, Rigetti, IonQ, OQC, Quandela, Anyon Systems, QuEra, Atom Computing and Quantinuum

 

 

²Inclusive of cash commitments in excess of $130M from the PIPE, in addition to approximately $24M from expected exercises of warrants prior to transaction close, in addition to cash proceeds of the RAAQ trust (assuming nil redemptions) and IQM existing cash as of 12/31/25, less expected transaction expenses of $25M

 

 

³ Exchange rate of EUR/USD of 1.174 as of December 31, 2025

 

 

⁴ Inclusive of cash commitments in excess of $130M from the PIPE, in addition to approximately $24M from expected exercises of warrants prior to transaction close, in addition to cash proceeds of the RAAQ trust (assuming nil redemptions) and IQM existing cash as of 12/31/25, less expected transaction expenses of $25M

 

 

⁵ Represent publicly announced on-premises deliveries from each of IBM, D-Wave, Pasqal, Rigetti, IonQ, OQC, Quandela, Anyon Systems, QuEra, Atom Computing and Quantinuum

 

 

Additional Information About the Proposed Transaction and Where to Find It

 

 

In connection with the proposed business combination, IQM intends to file with the SEC a registration statement on Form F-4 (the “Registration Statement”), which will include a preliminary proxy statement of RAAQ and a preliminary prospectus of IQM, and after the Registration Statement is declared effective by the SEC, RAAQ will mail the definitive proxy statement/prospectus relating to the proposed business combination to its shareholders as of a record date to be established for voting at the extraordinary general meeting of its shareholders (the “Extraordinary General Meeting”). The Registration Statement, including the proxy statement/prospectus contained therein, will contain important information about the proposed business combination and the other matters to be voted upon at the Extraordinary General Meeting. This communication does not contain all the information that should be considered concerning the proposed business combination and is not intended to provide the basis for any investment decision or any other decision in respect of such matters. RAAQ and IQM may also file other documents with the SEC regarding the proposed business combination. RAAQ’s shareholders and other interested persons are advised to read, when available, the Registration Statement, including the preliminary proxy statement/prospectus contained therein, the amendments thereto and the definitive proxy statement/prospectus and other documents filed in connection with the proposed business combination, as these materials will contain important information about RAAQ, IQM and the proposed business combination. Shareholders may obtain copies of the Registration Statement, including the preliminary or definitive proxy statement/prospectus contained therein, and the other documents filed or that will be filed by RAAQ and IQM with the SEC, once available, without charge, at the SEC’s website located at www.sec.gov.

 

 

Forward-Looking Statements

 

 

This communication includes “forward-looking statements” within the meaning of the U.S. federal securities laws and “forward-looking information” within the meaning of applicable non-U.S. securities laws (collectively, “forward-looking statements”). Forward-looking statements may be identified by the use of words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “will,” “expect,” “anticipate,” “believe,” “seek,” “target,” “continue,” “could,” “may,” “might,” “possible,” “potential,” “predict” or similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements are based upon current estimates and assumptions that, while considered reasonable by IQM and its management, and RAAQ and its management, as the case may be, are inherently uncertain. These statements include: projections of market opportunity and market share; estimates of customer adoption rates and usage patterns; projections regarding the Company’s ability to commercialize new products and technologies; projections of development and commercialization costs and timelines; expectations regarding the Company’s ability to execute its business model and the expected financial benefits of such model; expectations regarding the Company’s ability to attract, retain and expand its customer base; the Company’s deployment of proceeds from capital raising transactions; the Company’s expectations concerning relationships with strategic partners, suppliers, governments, state-funded entities, regulatory bodies and other third parties; the Company’s ability to maintain, protect and enhance its intellectual property; future ventures or investments in companies, products, services or technologies; development of favorable regulations affecting the Company’s markets; the successful consummation and potential benefits of the proposed business combination and expectations related to its terms and timing; the stock exchanges on which the securities of the combined company are expected to trade; proceeds from the business combination and related PIPE; funds received by the combined company from RAAQ’s trust account and redemptions by RAAQ’s public shareholders; the Company’s ability to commercialize its hardware and software; the expectation that the Company is building the sovereign infrastructure that allows quantum ecosystems to grow; and the potential for the Company to increase in value.

 

 

These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions, many of which are beyond the control of the Company and RAAQ.

 

 

These forward-looking statements are subject to known and unknown risks, uncertainties and assumptions that may cause the actual results of the combined company following the proposed transaction, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such statements. Such risks and uncertainties include: that the Company is pursuing an emerging technology, which faces significant technical challenges and may not achieve commercialization or market acceptance; the Company’s historical net losses and limited operating history; the Company’s expectations regarding future financial performance, capital requirements and unit economics; the Company’s use and reporting of business and operational metrics; the Company’s competitive landscape; the Company’s dependence on members of its senior management and its ability to attract and retain qualified personnel; the potential need for additional future financing; the Company’s concentration of revenue in contracts with government or state-funded entities; the Company’s ability to manage growth and expand its operations; potential future acquisitions or investments in companies, products, services or technologies; the Company’s reliance on strategic partners and other third parties; the Company’s ability to maintain, protect and defend its intellectual property rights; risks associated with privacy, data protection or cybersecurity incidents and related regulations; the use, rate of adoption and regulation of artificial intelligence and machine learning; uncertainty or changes with respect to laws and regulations; uncertainty or changes with respect to taxes, trade conditions and the macroeconomic environment; the combined company’s ability to maintain internal control over financial reporting and operate a public company; the possibility that required shareholder and regulatory approvals for the proposed transaction are delayed or are not obtained, which could adversely affect the combined company or the expected benefits of the proposed transaction; the risk that shareholders of RAAQ could elect to have their shares redeemed, leaving the combined company with insufficient cash to execute its business plans; the occurrence of any event, change or other circumstance that could give rise to the termination of the business combination agreement; the outcome of any legal proceedings or government investigations that may be commenced against the Company or RAAQ; failure to realize the anticipated benefits of the proposed transaction; the ability of IQM or the combined company to issue equity or equity-linked securities in connection with the proposed transaction or in the future; and other factors described in RAAQ’s and the Company’s filings with the SEC. These forward-looking statements are based on certain assumptions, including that none of the risks identified above materialize; that there are no unforeseen changes to economic and market conditions, and that no significant events occur outside the ordinary course of business. Additional information concerning these and other factors that may impact such forward-looking statements can be found in filings and potential filings by the Company, RAAQ or the combined company resulting from the proposed business combination with the SEC, including under the heading “Risk Factors.” If any of these risks materialize or assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. In addition, these statements reflect the expectations, plans and forecasts of the Company’s and RAAQ’s management as of the date of this communication; subsequent events and developments may cause their assessments to change. While the Company and RAAQ may elect to update these forward-looking statements at some point in the future, they specifically disclaim any obligation to do so, unless required by applicable securities laws. Accordingly, undue reliance should not be placed upon these statements.

 

 

In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this communication, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely upon these statements. An investment in RAAQ is not an investment in any of RAAQ’s founders’ or sponsors past investments, companies, or affiliated funds. The historical results of those investments are not indicative of future performance of RAAQ, which may differ materially from the performance of RAAQ’s founders’ or sponsors past investments.

 

 

Participants in the Solicitation

 

 

RAAQ, the Company and certain of their respective directors, executive officers and other members of management and employees may, under SEC rules, be deemed to be participants in the solicitation of proxies from RAAQ’s shareholders in connection with the proposed transaction. Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of RAAQ’s shareholders in connection with the proposed transaction will be set forth in the Registration Statement, including the proxy statement/prospectus contained therein, when it is filed with the SEC. You can find more information about RAAQ’s directors and executive officers in RAAQ’s final prospectus related to its initial public offering filed with the SEC on May 15, 2025 and in the subsequent Quarterly Reports on Form 10-Q filed by RAAQ with the SEC. Shareholders, potential investors, and other interested persons should read the Registration Statement, including the proxy statement/prospectus contained therein, carefully when it becomes available before making any voting or investment decisions. You may obtain free copies of these documents from the sources described above.

 

 

No Offer or Solicitation

 

 

This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction, including any European Economic Area member state or the United Kingdom. This communication is not, and under no circumstances is to be construed as, a prospectus, an advertisement or a public offering of the securities described herein in the United States or any other jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, or exemptions therefrom. Any potential dual listing of IQM’s ordinary shares on the Helsinki stock exchange referred to in this communication would be made by means of a prospectus as set out in the EU Prospectus Regulation. INVESTMENT IN ANY SECURITIES DESCRIBED HEREIN HAS NOT BEEN APPROVED BY THE SEC OR ANY OTHER REGULATORY AUTHORITY NOR HAS ANY AUTHORITY PASSED UPON OR ENDORSED THE MERITS OF THE OFFERING OR THE ACCURACY OR ADEQUACY OF THE INFORMATION CONTAINED HEREIN. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.

 

 

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260223639678/en/